Corient Private Wealth
AVDL

Corient Private Wealth’s Avadel Pharmaceuticals AVDL Stock Holding History

Corient Private Wealth’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-12,091
Closed -$125K – 2257
2023
Q3 		$125K Buy
12,091
+1,652
+16% +$22.1K ﹤0.01% 1993
2023
Q2 		$172K Buy
+10,439
New +$136K ﹤0.01% 1898

Other funds holding AVDL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Corient Private Wealth's AVDL Position: Q4 2023 in Review

Corient Private Wealth sold out of Avadel Pharmaceuticals (AVDL) in Q4 2023, closing a stake of 12,091 shares — an estimated $125K sold.

Corient Private Wealth first reported a position in AVDL in Q2 2023 and held it in 2 quarters. The position peaked at $172K in Q2 2023. 113 funds tracked by Wall St. Rank hold AVDL as of Q4 2023.

  • Corient Private Wealth reported no remaining Avadel Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Corient Private Wealth sold 12,091 Avadel Pharmaceuticals shares in Q4 2023, an estimated $125K.
  • Corient Private Wealth first reported a position in Avadel Pharmaceuticals in Q2 2023 and held it in 2 quarters.
  • Corient Private Wealth's Avadel Pharmaceuticals position peaked at $172K in Q2 2023.
  • 113 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2023.

Based on Corient Private Wealth's 13F filing for Q4 2023, filed 9 Feb 2024.